Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight loss ...
Clinical Pain Advisor16h
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Medical Marketing & Media14h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
News Nation on MSN19h
Scientists find natural molecule that works like Ozempic
BRINP2-related peptide, or BRP, is a naturally occurring molecule that can suppress appetite and promote weight loss in mice ...